Comparative Pharmacology
Head-to-head clinical analysis: FOLIC ACID versus NASCOBAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLIC ACID versus NASCOBAL.
FOLIC ACID vs NASCOBAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is a synthetic form of folate, a water-soluble B vitamin. It is reduced to dihydrofolate (DHF) and then to tetrahydrofolate (THF) via dihydrofolate reductase (DHFR). THF serves as a cofactor for one-carbon transfer reactions essential for purine and thymidine synthesis (DNA replication), amino acid metabolism (e.g., homocysteine remethylation to methionine), and other methylation reactions.
Vitamin B12 (cyanocobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
Oral or intramuscular/subcutaneous injection: 400-800 mcg daily for general supplementation; 1-5 mg daily for folate deficiency; 5-15 mg daily for megaloblastic anemia.
1 spray (500 mcg) intranasally once weekly.
None Documented
None Documented
Clinical Note
moderateFolic acid + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Folic acid."
Clinical Note
moderateTiaprofenic acid + Folic acid
"The therapeutic efficacy of Folic acid can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Folic acid
"The therapeutic efficacy of Folic acid can be decreased when used in combination with Carprofen."
Clinical Note
moderateCyproterone acetate + Folic acid
Terminal elimination half-life is approximately 0.7 hours (range 0.5-1.0 h) for folic acid; the active metabolite (5-MTHF) has a longer half-life of about 3-4 hours.
Approximately 6 days (depot effect due to slow release from injection site); for intramuscular doses, terminal elimination half-life is about 6 days due to gradual absorption
Primarily renal (urinary) as intact folic acid and metabolites, accounting for 80-90% of the excreted dose; fecal elimination via bile is minor (<10%).
Primarily renal (60-80% as unchanged drug), biliary/fecal (5-10%)
Category A/B
Category C
Vitamin
Vitamin
"The serum concentration of Folic acid can be decreased when it is combined with Cyproterone acetate."